BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food & Drug Administration (FDA) has granted EDG-5506 Orphan Drug Designation (ODD) for the treatment of Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker) and Rare Pediatric Disease Designation (RPDD) for the treatment of Duchenne. EDG-5506 is an investigational orally administered small molecule designed
Click here to view original post
News
VitriVax Awarded $3.6M Grant for Polio Vaccine Development
BOULDER, Colo.–(BUSINESS WIRE)–VitriVax Awarded $3.6M Grant from Gates Foundation for Polio Vaccine Development Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks
News
Less Physical Activity in Adolescence Likely Rooted in Physiology
The slowdown of physical activity during adolescence is not likely caused by lifestyle and environment but by energy demands placed on the body as it grows and sexually matures, according to a new study by […]
News
Policy Blog: SBIR/STTR Reauthorization, Colorado’s Budget Shortfall and Special Legislative Session, and PDAB’s Third UPL Rulemaking Hearing
This week’s policy blog includes federal and state updates on topics relevant to Colorado’s life sciences ecosystem: Reauthorization of SBIR/STTR Programs Colorado’s Budget Shortfall and Special Legislative Session Colorado PDAB’s Third Upper Payment Limit Rulemaking […]
